openPR Logo
Press release

Eppendorf continues on course for growth

06-15-2011 11:25 AM CET | Science & Education

Press release from: Eppendorf AG

Sustained sales growth
- Increased market share in Asia
- Sales before earnings and taxes up by 20.1 %

In the Life Science markets conditions improved with the economic recovery in the Financial Year 2010. While many companies made up their losses from the previous year which were due to the economic crisis, Eppendorf was able to consolidate its market position again during the reporting year. Eppendorf achieved a continued positive development of its performance.

The sales of the Eppendorf group increased to 484 million Euros in 2010, surpassing sales in the previous year by 11.7 percent (433,2 million Euros in the previous year).

International growth was mixed in the reporting year. While Asia showed the strongest growth with 19.9 percent, North America grew by 10.9 percent and, Europe exceeded previous year's sales by 8.4 percent.

There was a pleasant increase in earnings before interest and taxes by 20.1 percent from 77.9 million to 93.6 million Euros. The profit margin increased from 18.0 percent in 2009 to 19.4 percent in the reporting period. Annual profits were up by 20.8 percent and reached 59.3 million Euros (49.1 million Euros in the previous year).

The financial statement of the Eppendorf group confirms its extremely solid structure of the previous years and shows yet another improvement with an equity ratio of more than 58 percent in 2010 (55.3 percent in the previous year).

At the end of 2010, the Eppendorf group employed a total of 2622 people (2502 employees in the previous year).

"After the upheaval of the economic crisis of 2009 the economy was not yet back on solid footing in 2010. In spite of this, Eppendorf can look back on a successful year based on strong growth in Asia and the recovery of the European and US economies", comments Klaus Fink, CEO of Eppendorf AG who will swap the Chair of the Executive Board with the Chair of the Supervisory Board on May 1, 2011. On the same day, Dr. Dirk Ehlers will succeed him as CEO.

Eppendorf has an optimistic outlook for the future and expects a positive development in the current financial year 2011, with further growth in sales and earnings.

Eppendorf is a biotech company which develops, produces and distributes systems for use in all spheres of life science. The company's broad range of high quality products and systems is used by researchers worldwide to efficiently carry out their work.
The product range includes pipettes, dispensers and centrifuges as well as consumables such as micro test tubes and pipette tips. In addition to this, Eppendorf provides instruments and systems for automated liquid handling. Even a complete range of devices for DNA amplification for standard PCR or real-time PCR as well as systems for cell manipulation and electroporation are available. New Brunswick Scientific, Edison, USA, stands for expertise and top products within the Eppendorf Group in the field of cell growth, detection and storage.
Eppendorf products are designed for academic and commercial research facilities, but also for industrial companies in the field of biotechnology and in other sectors using biotech research processes. Innovative research approaches will call for miniature applications with an increased sample throughput for future diagnostics and therapy. This implies a trend towards automation and a level of reproducibility for which the company's high level of technology and expertise will be sought after on the market.
Eppendorf is represented in all important markets worldwide. Although the company is placing main emphasis on North America as the regional market, Asia has a high potential with dynamic rates of growth.
Eppendorf was founded in Hamburg in 1945 and has more than 2500 employees worldwide. The company has subsidiaries in 18 countries and is represented in many other markets by distributors.

Eppendorf AG
Bettina Doerler
public relations officer
Barkhausenweg
22339 Hamburg
doerler.b@eppendorf.de
+49 40 538 01-640

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Eppendorf continues on course for growth here

News-ID: 179347 • Views:

More Releases from Eppendorf AG

Behind the scenes with Eppendorf
New video provides unique insight into manufacturing and production of consumables Eppendorf is providing an exclusive behind the scenes video look at the production of consumables and providing insight into the company’s exceptional quality control throughout the whole manufacturing process. The new video, available on the company’s website, demonstrates Eppendorf’s commitment to delivering consistently high quality and reliable consumables for the laboratory. Take a tour at www.eppendorf.com/consumablesmovie or eppendorf.com/youtubeconsumables. Dr. Sirkka
Behind the scenes with Eppendorf
New video provides unique insight into manufacturing and production of consumables Eppendorf is providing an exclusive behind the scenes video look at the production of consumables and providing insight into the company’s exceptional quality control throughout the whole manufacturing process. The new video, available on the company’s website, demonstrates Eppendorf’s commitment to delivering consistently high quality and reliable consumables for the laboratory. Take a tour at www.eppendorf.com/consumablesmovie or eppendorf.com/youtubeconsumables. Dr. Sirkka
New Nature Podcast with Eppendorf Award Winner 2011
New Nature Podcast with Eppendorf Award Winner 2011
Suzan Rooijakkers, PhD, speaks about her research on Staphylococcus aureus. In 2011, the Eppendorf Award for Young European Investigators was awarded to Assistant Professor Suzan Rooijakkers, PhD, (University Medical Center Utrecht, Department of Medical Microbiology, Utrecht, The Netherlands) for her discoveries of how the pathogen Staphylococcus aureus evades immune attack to survive in the human host. Listen now to the interview that Geoff Marsh (Podcast Editor of Nature Publishing Group, London)
New software speeds validation of automated liquid handling processes
New software speeds validation of automated liquid handling processes Eppendorf’s epMotion® GxP solution includes an automated pipetting system, epBlue™ GxP software and certificates, plus dedicated certification and validation services (like IQ/OQ and user trainings). Automation increases the speed and accuracy of liquid handling and now the new epMotion GxP cuts the time required to validate these processes and comply to European and US government requirements. For biomedical and pharmaceutical companies, as

All 5 Releases


More Releases for Euros

Manage to win 500 Euros!
Well, my friends, it gets very hot! And not only because of the abnormal heat, but also among the participants of the Summer Promotion! This time a huge number of our clients participate in the Promotion, which means that the competition for the main prize is growing every day. We are even thinking of extending our Promotion and adding another main prize for you! Well, interesting, right? If you have not
The Penki Kontinentai Group Scores 47 Million Euros in Revenue
The Penki Kontinentai group, which has been operating in the field of IT technologies almost for 30 years, showed high financial results in 2018. Its income amounted to 47 million euros (in 2017 - 34 million euros). A company owned by the group, Penkių kontinentų bankinės technologijos (BS/2), achieved the most significant results in 2018. It implemented a number of projects for more than 5 million euros only in Kazakhstan and
Plant Extension for Six Million Euros
Halver, 26 April 2018 – The ESCHA Group is extending its production- and logistics hub commissioned in January 2017 by 4,700 square meters of production- and office area. The site activities for the second building phase started on 26 April 2018. The industrial connectivity specialist is making an investment of about six million euros for the two-level production building with a four-level office wing. On a scheduled basis, the second
4 million euros for Open Banking platform NDGIT
NDGIT opens banks and insurers up for digital business models via APIs - Joint investment from Capnamic Ventures as lead investor and PROfounders as international partner in London - NDGIT plans international expansion and further development of its technology Munich – 25 April 2018: NDGIT (https://nextdigitalbanking.com) offers banks and insurers an Open Banking platform that enables them to connect to new business models and to share data in accordance with PSD2. With 4
Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG
Vaccine Specialist AFFiRiS AG successfully completes Financing Round • € 10m additional capital raised • Supervisory Board appoints Oliver Siegel as Chief Executive Officer • Prof. Dr. Christoph Huber elected to Supervisory Board AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the
URALCHEM to Give 100,000 Euros to Schools in Riga
Riga, Latvia - February 11, 2013 -- OJSC URALCHEM (uralchem.com), the Ziedot.lv Fund and two secondary schools in Riga have agreed to carry out a joint charity project. A memorandum was signed by URALCHEM CEO Dmitry Konyaev, Manager of the Fund Ziedot.lv Ruta Dimanta and the headmasters of the schools, Iveta Stivrinya and Boris Antonov. Within the framework of the project, URALCHEM will provide funding to the amount of more than